Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Mel-PTCy vs Flu-Mel-ATG RIC Allogeneic HCT (BHS)
2024-518568-11-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Oct 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclophosphamide and antithymocyte globulin rabbit in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML) and 7 more (2 arms), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoint: Current GVHD-free, relapse-free survival (cGRFS). Planned start Oct 2024; status: authorised.
02
Drugs
cyclophosphamideantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)myeloproliferative disorder (MPD)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on 2024-518568-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518568-11-00.